Company intelligence / Profile preview
Rejuvenate Bio
- Ownership
- Private
- Employees
- ~11
- Development stage
- Preclinical
Overview
Rejuvenate Bio has demonstrated preclinical efficacy of its gene therapies in reversing age-related changes and extending lifespan in mice using partial cellular reprogramming. Its lead candidate RJB‑0402 is advancing toward clinical trials for arrhythmogenic cardiomyopathy with support from a $4M CIRM grant. The company’s therapies have also shown safety and efficacy in canine models of heart disease
- Therapeutic areas
- Metabolic DisordersEndocrinologyRheumatologyCardiovascularNeurology
- Modalities
- Gene therapyAAV-based gene therapyEpigenetic reprogramming (via Yamanaka factors)Protein (FGF21)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Rejuvenate Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rejuvenate Bio.